Search results for "DYSLIPIDEMIA"

showing 10 items of 287 documents

Determinants of HIV outpatient service utilization according to HIV parameters

2014

Introduction : The increased life expectancy of HIV patients in the era of highly active antiretroviral therapy has had profound consequences for the healthcare systems that provide their care. It is useful to assess whether healthcare resources need to be adapted to the different stages of HIV infection or to patient characteristics [1]. To study how patient features influence utilization of out patient services, we retrospectively analyzed the electronic health record of HIV-positive patients who had followed day-care programs at the AIDS Center of the University of Palermo, Italy. Materials and Methods : 223 HIV-infected subjects were recruited and divided into two groups according to CD…

Pediatricsmedicine.medical_specialtySettore MED/17 - Malattie Infettivebusiness.industryPublic Health Environmental and Occupational HealthDay careSettore MED/42 - Igiene Generale E ApplicataLogistic regressionmedicine.diseaseHIV outpatient serviceSubstance abuseInfectious DiseasesPharmacotherapyHIV Health care outpatientsAcquired immunodeficiency syndrome (AIDS)Poster Sessions – Abstract P079Health caremedicineLife expectancybusinessDyslipidemiaJournal of the International AIDS Society
researchProduct

Natural products and analogs as preventive agents for metabolic syndrome via peroxisome proliferator-activated receptors: An overview.

2021

Abstract Natural products and synthetic analogs have drawn much attention as potential therapeutical drugs to treat metabolic syndrome. We reviewed the underlying mechanisms of 32 natural products and analogs with potential pharmacological effects in vitro, and especially in rodent models and/or patients, that usually act on the PPAR pathway, along with other molecular targets. Recent outstanding total syntheses or semisyntheses of these lead compounds are stated. In general, they can activate the transcriptional activity of PPARα, PPARγ, PPARα/γ, PPARβ/δ, PPARα/δ, PPARγ/δ and panPPAR as weak, partial agonists or selective PPARγ modulators (SPPARγM), which may be useful for managing obesity…

Peroxisome Proliferator-Activated ReceptorsPeroxisome proliferator-activated receptorPharmacologyResveratrol01 natural sciences03 medical and health scienceschemistry.chemical_compoundStructure-Activity RelationshipBerberineDrug DiscoverymedicineAnimalsHumansReceptor030304 developmental biologyPharmacologychemistry.chemical_classificationMetabolic Syndrome0303 health sciencesBiological ProductsDose-Response Relationship DrugMolecular Structure010405 organic chemistryChemistryOrganic ChemistryGeneral MedicinePPAR Pathwaymedicine.disease0104 chemical sciencesCurcuminQuercetinDyslipidemiaEuropean journal of medicinal chemistry
researchProduct

Emerging approaches for the treatment of hypertriglyceridemia.

2013

Hypertriglyceridemia is frequent in diabetic and obese subjects, who are at increased risk for cardiovascular diseases (CVD). Increased triglycerides (TG) are a hallmark of atherogenic dyslipidemia, representing a marker of atherogenic small dense low-density lipoproteins (sdlDL). Importantly, non-fasting/postprandial TG measurements tend to be emphasized in clinical practice for the prediction of CVD, and TG-lowering agents (primarily fibrates) have a beneficial effect on atherogenic dyslipidemia, reducing TG-rich particles and ultimately lowering the production of sdlDL. The combination of omega-3 fatty acids and statins is also recommended, and widely used in clinical practice for subjec…

PharmacologyHypertriglyceridemiamedicine.medical_specialtyAtherogenic dyslipidemiabusiness.industryHypertriglyceridemiaGeneral Medicinemedicine.diseaseBioinformaticsFish consumptionClinical PracticeEndocrinologyIncreased riskPostprandialInternal medicinecardiovascular diseases triglycerides hypertriglyceridemia triglyceride-lowering agentsmedicineIncreased triglyceridesHumansPharmacology (medical)Obese subjectsbusinessLife StyleHypolipidemic AgentsExpert opinion on pharmacotherapy
researchProduct

Lipid-lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel

2017

In recent years, there has been growing interest in the possible use of nutraceuticals to improve and optimize dyslipidemia control and therapy. Based on the data from available studies, nutraceuticals might help patients obtain theraputic lipid goals and reduce cardiovascular residual risk. Some nutraceuticals have essential lipid-lowering properties confirmed in studies; some might also have possible positive effects on nonlipid cardiovascular risk factors and have been shown to improve early markers of vascular health such as endothelial function and pulse wave velocity. However, the clinical evidence supporting the use of a single lipid-lowering nutraceutical or a combination of them is…

PhytochemicalsMedicine (miscellaneous)030204 cardiovascular system & hematologyPharmacologyIntestinal absorption0302 clinical medicineRisk FactorsDrug Interactions030212 general & internal medicineRandomized Controlled Trials as TopicNutrition and DieteticsEvidence-Based MedicineOrvostudományok3. Good healthObservational Studies as TopicLiverCardiovascular DiseasesFatty Acids Unsaturatedlipids (amino acids peptides and proteins)nutraceuticalposition papermedicine.medical_specialtyStatinCombination therapymedicine.drug_classKlinikai orvostudományok03 medical and health sciencesMeta-Analysis as TopiclipidmedicineHumansIntensive care medicineLife StyleTriglyceridesDyslipidemiasbusiness.industryProbioticsdyslipidemiaCholesterol HDLEvidence-based medicineCholesterol LDLmedicine.diseaseResidual riskIntestinal AbsorptionrecommendationsDietary SupplementsPosition paperObservational Studies as TopicHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessDyslipidemia
researchProduct

Prevention, diagnosis, and treatment of obesity. 2016 position statement of the Spanish Society for the Study of Obesity.

2017

Position statementAdultMaleSpanish Society for the Study of ObesityPALABRASPediatricsmedicine.medical_specialtyPediatric ObesityMEDLINEBariatric SurgeryComorbidity030204 cardiovascular system & hematologyModels BiologicalComorbidities03 medical and health sciencesDisease susceptibility0302 clinical medicineSleep Apnea SyndromesDiabetes mellitusDiagnosismedicinePrevalenceHumans030212 general & internal medicineObesityChildExerciseAdiposityDyslipidemiasInflammationbusiness.industryPreventionmedicine.diseaseObesityComorbidityDietTreatmentDiabetes Mellitus Type 2Cardiovascular DiseasesSpainBody CompositionFemaleAnti-Obesity AgentsDisease SusceptibilitybusinessEnergy IntakeEndocrinologia, diabetes y nutricion
researchProduct

Low physical activity and its association with diabetes and other cardiovascular risk factors: a nationwide, population-based study

2016

Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM; ISCIII Ministerio de Ciencia e Innovacion); Ministerio de Sanidad y Consumo; Spanish Diabetes Society (SED)

QuestionnairesMaleDislipidemiasCross-sectional studyEstudios transversalesEspañaObesidadÍndice de masa corporalBiochemistryBody Mass Index0302 clinical medicineEndocrinology:Phenomena and Processes::Musculoskeletal and Neural Physiological Phenomena::Musculoskeletal Physiological Phenomena::Musculoskeletal Physiological Processes::Movement::Motor Activity [Medical Subject Headings]Public and Occupational Healthlcsh:Science:Phenomena and Processes::Physiological Phenomena::Nutritional Physiological Phenomena::Diet::Diet Mediterranean [Medical Subject Headings]:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Data Collection::Vital Statistics::Morbidity::Prevalence [Medical Subject Headings]:Chemicals and Drugs::Lipids::Glycerides::Triglycerides [Medical Subject Headings]:Geographicals::Geographic Locations::Europe::Spain [Medical Subject Headings]Aged 80 and overDiabetis:Diseases::Nutritional and Metabolic Diseases::Metabolic Diseases::Lipid Metabolism Disorders::Dyslipidemias [Medical Subject Headings]:Phenomena and Processes::Physiological Phenomena::Body Constitution::Body Weights and Measures::Body Size::Body Weight::Overweight::Obesity::Obesity Abdominal [Medical Subject Headings]Cardiovascular DiseasesObesitatEnfermedades cardiovascularesFactores de riesgomedicine.medical_specialtyEndocrine Disorders:Chemicals and Drugs::Lipids::Lipoproteins::Lipoproteins HDL::Cholesterol HDL [Medical Subject Headings]:Psychiatry and Psychology::Behavior and Behavior Mechanisms::Behavior::Habits::Smoking [Medical Subject Headings]QüestionarisTriglicéridosExercici -- Aspectes sanitaris03 medical and health sciencesDiabetes MellitusHumans:Diseases::Cardiovascular Diseases [Medical Subject Headings]ExerciseAgedSurvey ResearchMalalties cardiovascularsPreventionlcsh:REnfermedad crónicaBiology and Life SciencesPhysical ActivityInsulin-resistancemedicine.diseaseActividad motoraObesityLipid metabolismCross-Sectional StudiesDyslipidemiaAdherenceGlucosalcsh:QBody mass indexDyslipidemiaDemography:Psychiatry and Psychology::Behavior and Behavior Mechanisms::Psychology Social::Life Style::Sedentary Lifestyle [Medical Subject Headings]PhysiologyPhysical fitnessSistema cardiovascular -- Malalties:Chemicals and Drugs::Carbohydrates::Monosaccharides::Hexoses::Glucose [Medical Subject Headings]lcsh:Medicine:Phenomena and Processes::Physiological Phenomena::Body Constitution::Body Weights and Measures::Body Size::Body Weight::Overweight::Obesity [Medical Subject Headings]:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Probability::Risk::Risk Factors [Medical Subject Headings]Obesidad abdominalGeographical LocationsGlucose MetabolismRisk FactorsHábito de fumarMedicine and Health SciencesPrevalence030212 general & internal medicinePrediabetes:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Data Collection::Surveys and Questionnaires [Medical Subject Headings]Multidisciplinary:Diseases::Pathological Conditions Signs and Symptoms::Pathologic Processes::Disease Attributes::Chronic Disease [Medical Subject Headings]DiabetesMiddle Aged:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cross-Sectional Studies [Medical Subject Headings]EuropeEncuestas y cuestionariosPhysiological ParametersResearch DesignCarbohydrate MetabolismFemaleResearch ArticleAdultAdolescent030209 endocrinology & metabolismVida sedentariaResearch and Analysis MethodsHDL-colesterolYoung AdultSex FactorsDiabetes mellitusmedicineAdultsObesityEspanya:Diseases::Endocrine System Diseases::Diabetes Mellitus::Prediabetic State [Medical Subject Headings]Sedentary lifestylebusiness.industryEstado prediabéticoBody WeightPhysical fitnessDieta mediterráneaMetabolisme dels lípidsDietMetabolismSpainMetabolic DisordersPeople and PlacesPhysical therapySedentary BehaviorbusinessPrevalenciaCondició física
researchProduct

La diabetes mellitus y el riesgo cardiovascular. ¿Es necesario el tratamiento integral de la diabetes mellitus tipo 2 y los factores de riesgo cardio…

2010

ResumenLas enfermedades cardiovasculares (CV) son la primera causa de muerte en la población española, tanto en personas diabéticas como no diabéticas. En la diabetes, la enfermedad CV es entre 2 y 4 veces más frecuente, más precoz y más agresiva. Con las medidas actuales se puede llegar a una prevención del ∼50% de la enfermedad CV. Los factores de riesgo CV en la diabetes son la hipertensión arterial (HTA), la dislipemia, el tabaquismo, la obesidad y el sedentarismo. Más del 80% de pacientes con diabetes tipo 2 presenta HTA y dislipemia, y aproximadamente un 15% sigue fumando. Pero menos de un 10% tiene todos estos factores controlados. Aunque la dislipemia es el factor más condicionante …

Riskmedicine.medical_specialtymedicine.medical_treatmentEnfermedad cardiovascularDiseaseType 2 diabetesRiesgoDiabetes tipo 2Internal medicineDiabetes mellitusmedicineCause of deathMedicine(all)business.industryPreventionType 2 diabetesGeneral MedicineAtención primariaCardiovascular diseasePrimary caremedicine.diseaseObesityPrevenciónBlood pressureSmoking cessationbusinessFamily PracticeDyslipidemiaAtención Primaria
researchProduct

Tratamiento hipolipemiante en los pacientes con enfermedad cardiovascular de riesgo muy elevado. Documento de consenso SEC sobre las indicaciones de …

2021

Different primary and secondary prevention studies have documented that a greater degree of reduction in low-density lipoprotein cholesterol (LDL-C) levels is associated with a greater decrease in cardiovascular event rates. PCSK9 inhibitors achieve important, rapid and sustained decreases in LDL-C. New clinical practice guidelines for the management of dyslipidemia establish reduced target levels of LDL-C. These goals are hardly achievable with a statin-only treatment, even in combination with ezetimibe. The addition of PCSK9 inhibitors can play a determining role in achieving these recommendations. However, it is important to identify the patient subgroups that can most benefit from this …

Secondary preventionGynecologyCardiovascular eventmedicine.medical_specialtybusiness.industryPatient subgroupsmedicine.diseaseClinical PracticeEzetimibemedicinelipids (amino acids peptides and proteins)Cardiology and Cardiovascular MedicinebusinessPCSK9 InhibitorsDyslipidemiaLipoprotein cholesterolmedicine.drugREC: CardioClinics
researchProduct

Use of Combination Statin and Bile Acid Sequestrant Therapy to Treat Dyslipidemia

2015

Lipid management guidelines promulgated around the world continue to emphasize the need to reduce serum levels of low-density lipoprotein cholesterol (LDL-C) in order to reduce risk for acute cardiovascular events in both the primary and secondary prevention settings [1–3]. There is growing consensus that when it comes to LDL-C management, lower is better with no apparent lower limit that is discernible from current evidence, i.e., there is greater and greater benefit as LDL-C decreases with no apparent loss in safety [4–8]. Dyslipidemia and coronary artery disease (CAD) are widely prevalent throughout the world. Considerable effort continues to be focused on expanding the appropriate use o…

Secondary preventionmedicine.medical_specialtyStatinBile acidbusiness.industrymedicine.drug_classmedicine.diseaseAppropriate useCoronary artery diseaseBile acid sequestrantMedicinelipids (amino acids peptides and proteins)businessIntensive care medicineDyslipidemiaLipoprotein cholesterol
researchProduct

NEXT GENERATION SEQUENCIN: A NEW METHODOLOGICAL APPROACH FOR THE MOLECULAR DIAGNOSIS OF GENETIC DYSLIPIDEMIAS

2014

Settore MED/09 - Medicina InternaNGS DYSLIPIDEMIAS
researchProduct